A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
18 Years
N/A
Both
Melanoma (Skin)
Trial Information
A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma
OBJECTIVES:
Primary
- Determine the safety of adjuvant vaccine therapy comprising multi-epitope melanoma
peptides (MP) and multi-epitope melanoma helper peptides (MHP) emulsified in Montanide
ISA-51 in patients with resected stage IIB-IV melanoma.
- Determine the safety of administering cyclophosphamide before vaccination in these
patients.
- Compare the magnitude of immune response against vaccination comprising MP in
combination with either MHP or tetanus toxoid helper peptide (TET) emulsified in
Montanide ISA-51 with vs without cyclophosphamide in these patients.
Secondary
- Compare the response rate and persistence of immune responses in patients treated with
these regimens.
- Compare the magnitude of immune response against vaccination comprising TET or MHP with
vs without cyclophosphamide in these patients.
- Compare the response rate and persistence of immune response against vaccination
comprising TET or MHP with vs without cyclophosphamide in these patients.
- Determine the delayed-type hypersensitivity response to the peptide components of these
vaccines in these patients.
- Compare, preliminarily, disease-free survival of patients treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
according to HLA-type (HLA-A1 positive vs HLA-A2 positive, HLA-A1 negative, or -A3 negative
vs HLA-A3 positive, or -A1 negative) and participating center (University of Virginia [UVA]
vs non-UVA). Patients are randomized to 1 of 4 treatment arms.
- Arm I: Patients receive vaccine comprising multi-epitope melanoma peptides (MP) and
tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally (ID) and
subcutaneously (SC) on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.
- Arm II: Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients
then receive vaccine as in arm I.
- Arm III: Patients receive vaccine comprising MP and multi-epitope melanoma helper
peptides emulsified in Montanide ISA-51 ID and SC on days 1, 8, 15, 29, 36, 43, 85,
183, 274, and 365.
- Arm IV: Patients receive cyclophosphamide as in arm II. Patients then receive vaccine
as in arm III.
Treatment in all arms continues in the absence of disease progression or unacceptable
toxicity.
After completion of study treatment, patients are followed every 6 months for 2 years and
then annually thereafter.
PROJECTED ACCRUAL: A total of 173 patients will be accrued for this study within 2 years.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed melanoma
- Cutaneous, mucosal, or primary melanoma
- Stage IIB-IV disease
- Has undergone surgical resection or stereotactic radiosurgery for malignant melanoma
≥ 1 week but ≤ 6 months ago
- No clinical or radiological evidence of disease after surgical resection or
stereotactic radiosurgery by chest x-ray or CT scan*, abdominal and pelvic CT
scan*, and head CT scan or MRI NOTE: *Positron emission tomography scan/CT
fusion scan may replace scans of the chest, abdomen, and pelvis
- Must have ≥ 2 intact (undissected) axillary and/or inguinal lymph node basins
- HLA-A1, -A2, or -A3 positive AND HLA-DR1, -DR4, -DR11, -DR13, or -DR15 positive
- Ineligible for OR refused interferon
- No ocular melanoma
- Brain metastases allowed provided all of the following criteria are met:
- No more than 3 total brain metastases
- Each metastasis ≤ 2 cm in diameter at the time of study entry
- Each metastasis was completely removed by surgery or treated with stereotactic
radiosurgery
- No evidence of brain metastasis progression since the most recent treatment
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count > 1,000/mm^3
- Platelet count > 100,000/mm^3
- Hemoglobin > 9 g/dL
Hepatic
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ 2.5 times ULN
- Lactic dehydrogenase ≤ 1.5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN
- Hepatitis C negative
Renal
- Creatinine ≤ 1.5 times ULN
Cardiovascular
- No New York Heart Association class III or IV heart disease
Immunologic
- HIV negative
- No known or suspected allergy to any component of the study vaccines
- No autoimmune disorder with visceral involvement
- No prior or active autoimmune disorder requiring cytotoxic or immunosuppressive
therapy
- The following immunologic conditions are allowed:
- Laboratory evidence of autoimmune disease (e.g., positive anti-nuclear antibody
titer) without symptoms
- Clinical evidence of vitiligo
- Other forms of depigmenting illness
- Mild arthritis requiring non-steroidal anti-inflammatory drugs
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Weight ≥ 110 lbs
- No uncontrolled diabetes
- Hemoglobin A1C < 7%
- No medical contraindication or potential problem that would preclude study compliance
- No other malignancy except squamous cell or basal cell skin cancer without known
metastasis, carcinoma in situ of the breast (ductal or lobular) or cervix, or other
successfully treated cancer without distant metastasis with no evidence of recurrence
or metastasis for > 5 years
- No known active addiction to alcohol or drugs
- No recent (within the past year) or ongoing illicit IV drug use
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior vaccination with any of the synthetic peptides used in this study
- Prior vaccinations (containing agents other than the synthetic peptides used in
this study) that resulted in recurrent disease during or after vaccine
administration allowed provided the last vaccination was administered more than
12 weeks ago
- More than 4 weeks since prior and no concurrent interferon (e.g., Intron-A®),
interleukins (e.g., Proleukin®), or growth factors (e.g., Procrit®, Aranesp®, or
Neulasta®)
- More than 4 weeks since prior and no concurrent allergy desensitization injections
- No influenza vaccines for at least 2 weeks before or after study vaccine
administration
Chemotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
- No concurrent chemotherapy, including nitrosoureas
Endocrine therapy
- More than 4 weeks since prior and no concurrent oral or parenteral corticosteroids
- No prior or concurrent inhaled steroids (e.g., Advair®, Flovent®, or Azmacort®)
- Prior or concurrent topical corticosteroids allowed
Radiotherapy
- See Disease Characteristics
- More than 4 weeks since other prior and no concurrent radiotherapy
Surgery
- See Disease Characteristics
Other
- More than 4 weeks since prior and no other concurrent investigational agents
- More than 30 days since prior and no concurrent participation in another clinical
study
Type of Study:
Interventional
Study Design:
Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety if less than 33% of patients experience a dose-limiting toxicity up to week 52
Safety Issue:
Yes
Principal Investigator
Craig L. Slingluff, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Virginia
Authority:
United States: Federal Government
Study ID:
CDR0000430929
NCT ID:
NCT00118274
Start Date:
March 2005
Completion Date:
Related Keywords:
- Melanoma (Skin)
- stage II melanoma
- stage III melanoma
- stage IV melanoma
- Melanoma
Name | Location |
|---|---|
| M. D. Anderson Cancer Center at University of Texas | Houston, Texas 77030-4009 |
| University of Virginia Cancer Center | Charlottesville, Virginia 22908 |
| Fox Chase Cancer Center - Philadelphia | Philadelphia, Pennsylvania 19111-2497 |
